Cannara Biotech Inc.
Cannara Biotech Inc. (LOVFF) Revenue
Annual & quarterly revenue history · segment & region breakdown
LOVFF · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsCannara Biotech Inc. trailing twelve-month (TTM) revenue is $0.11B, an increase of 31.28% year-over-year from $0.11B in FY2025.
Revenue trend
2025 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-08-31 | $0.11B | +$0.03B | +31.28% |
| 2024-08-31 | $0.08B | +$0.02B | +42.77% |
| 2023-08-31 | $0.06B | +$0.02B | +59.76% |
| 2022-08-31 | $0.04B | +$0.02B | +110.58% |
| 2021-08-31 | $0.02B | +$0.01B | +567.24% |
| 2020-08-31 | $0.00B | +$0.00B | +21.64% |
| 2019-08-31 | $0.00B | +$0.00B | +384.70% |
| 2018-08-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Cannara Biotech Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Cannara Biotech Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CAD.
Data sourced from Cannara Biotech Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
LOVFF revenue · 4 questionsLOVFF's trailing twelve-month (TTM) revenue is $0.11B. That is an increase of 31.28% year-over-year from $0.11B in FY2025.
▸ Source: FMP · Cannara Biotech Inc. SEC filings · GAAP · Cannara Biotech Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026